Biotechnologies Assets SA (BST.MC)

EUR 0.31

(-4.35%)

Net Debt Summary of Biotechnologies Assets SA

Biotechnologies Assets SA's latest annual net debt in 2023 was 6.81 Million EUR , up 125.19% from previous year.
Biotechnologies Assets SA's latest quarterly net debt in 2023 FY was 6.81 Million EUR , up 125.19% from previous quarter.
Biotechnologies Assets SA reported annual net debt of 3.02 Million EUR in 2022, up 59.3% from previous year.
Biotechnologies Assets SA reported annual net debt of 1.89 Million EUR in 2021, down -28.3% from previous year.
Biotechnologies Assets SA reported quarterly net debt of 6.81 Million EUR for 2023 Q4, up 82.13% from previous quarter.
Biotechnologies Assets SA reported quarterly net debt of 3.7 Million EUR for 2023 Q1, up 22.48% from previous quarter.

Annual Net Debt Chart of Biotechnologies Assets SA (2023 - 2010)

Historical Annual Net Debt of Biotechnologies Assets SA (2023 - 2010)

Year	Net Debt	Net Debt Growth
2023	6.81 Million EUR	125.19%
2022	3.02 Million EUR	59.3%
2021	1.89 Million EUR	-28.3%
2020	2.64 Million EUR	-84.28%
2019	16.85 Million EUR	-60.68%
2018	42.85 Million EUR	6417.4%
2017	657.5 Thousand EUR	-34.96%
2016	1.01 Million EUR	-82.02%
2015	5.62 Million EUR	20.77%
2014	4.65 Million EUR	4122.94%
2013	-115.73 Thousand EUR	-145.06%
2012	256.82 Thousand EUR	118.1%
2011	-1.41 Million EUR	-6541.04%
2010	-21.36 Thousand EUR	0.0%

Year	Net Debt	Net Debt Growth
2023 Q2	3.51 Million EUR	-5.23%
2023 Q4	6.81 Million EUR	82.13%
2023 Q1	3.7 Million EUR	22.48%
2023 Q3	3.74 Million EUR	6.52%
2023 FY	6.81 Million EUR	125.19%
2022 FY	3.02 Million EUR	59.3%
2022 Q2	2 Million EUR	0.0%
2022 Q4	3.02 Million EUR	0.0%
2021 Q2	3.27 Million EUR	0.0%
2021 Q4	1.89 Million EUR	0.0%
2021 FY	1.89 Million EUR	-28.3%
2020 FY	2.64 Million EUR	-84.28%
2020 Q2	18.66 Million EUR	0.0%
2020 Q4	2.64 Million EUR	0.0%
2019 FY	16.85 Million EUR	-60.68%
2019 Q4	16.85 Million EUR	0.0%
2019 Q2	17.72 Million EUR	0.0%
2018 FY	42.85 Million EUR	6417.4%
2018 Q4	42.85 Million EUR	0.0%
2018 Q2	17.23 Million EUR	0.0%
2017 Q4	657.5 Thousand EUR	0.0%
2017 FY	657.5 Thousand EUR	-34.96%
2017 Q2	1.1 Million EUR	0.0%
2016 Q2	236.54 Thousand EUR	0.0%
2016 Q4	1.01 Million EUR	0.0%
2016 FY	1.01 Million EUR	-82.02%
2015 Q4	5.62 Million EUR	0.0%
2015 FY	5.62 Million EUR	20.77%
2015 Q2	5.45 Million EUR	0.0%
2014 Q4	4.65 Million EUR	0.0%
2014 Q2	3.16 Million EUR	0.0%
2014 FY	4.65 Million EUR	4122.94%
2013 Q4	-115.73 Thousand EUR	0.0%
2013 FY	-115.73 Thousand EUR	-145.06%
2013 Q2	219 Thousand EUR	0.0%
2012 Q2	3.07 Million EUR	0.0%
2012 FY	256.82 Thousand EUR	118.1%
2012 Q4	256.82 Thousand EUR	0.0%
2011 Q4	-1.41 Million EUR	0.0%
2011 Q2	3.34 Million EUR	0.0%
2011 FY	-1.41 Million EUR	-6541.04%
2010 FY	-21.36 Thousand EUR	0.0%
2010 Q4	-21.36 Thousand EUR	0.0%

Peer Net Debt Comparison of Biotechnologies Assets SA

Name	Net Debt	Net Debt Difference
Atrys Health, S.A.	212.17 Million EUR	96.788%
Oryzon Genomics S.A.	1.43 Million EUR	-376.439%
Pharma Mar, S.A.	-16.65 Million EUR	140.914%
Laboratorios Farmaceuticos Rovi, S.A.	40.1 Million EUR	83.008%